Neurizon Expands ALS Trial to 240 Participants With Results Now Due Sooner
HEALEY ALS Platform Trial Regimen I expands to 240 participants — with no change to funding requirements
Neurizon Therapeutics Limited (ASX: NUZ) has announced the expansion of Regimen I of the HEALEY ALS Platform Trial from 160 to 240 participants, comprising 180 NUZ-001 participants and 60 Regimen I placebo controls. The expansion is driven by enrolment exceeding original expectations and the absence of a concurrent regimen during the recruitment period. Critically, despite the higher participant target, the accelerated pace means topline results are now expected in early Q3 CY2027, ahead of the previously stated schedule, with no change to the Company’s funding requirements through to that readout.
As of 22 May 2026, 113 participants have been assigned to Regimen I and 74 have been dosed, with 64 US clinical trial sites activated and 193 participants screened to date under the master protocol.
When big ASX news breaks, our subscribers know first
Why the trial is growing — and why it’s good news for investors
Enrolment momentum is the catalyst
The decision to expand is a direct consequence of recruitment running materially ahead of schedule, compounded by the absence of a competing regimen operating in parallel during the expected recruitment window. This is, by any measure, a quality outcome rather than a corrective one. The trial design is being proactively optimised from a position of strength.
Notably, the accelerated enrolment pace offsets the higher recruitment target. Despite adding 80 participants to the cohort, last participant dosing is now projected for Q2 CY2027, with topline results following in early Q3 CY2027, both ahead of prior projections.
What the larger dataset unlocks
Expanding to 240 participants delivers meaningful scientific and commercial advantages over the original 160-participant design. The announcement confirms the expanded design:
- Maintains statistical power for the primary endpoint, aligned with the original trial assumptions
- Enables more robust subgroup and biomarker analysis
- Eliminates cross-regimen placebo dependency, removing reliance on placebo groups from other regimens
- Generates a larger, internally consistent ALS dataset that strengthens regulatory and partnering positioning
For investors, this is material. A more statistically robust and internally consistent dataset carries greater weight in regulatory submissions and partnership negotiations than one that depends on external placebo groups.
Understanding the HEALEY ALS Platform Trial — and why it matters
The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in the United States. It was created in partnership with the Network of Excellence for ALS (NEALS).
An adaptive Phase 2/3 trial uses a flexible master protocol that allows researchers to test multiple treatments simultaneously while adjusting the design based on accumulating data, all within a single, pre-approved framework. This approach accelerates the development of potential new therapies without sacrificing scientific rigour.
Entry into the HEALEY ALS Platform Trial is competitive. Drug candidates are reviewed and selected by expert committees based on scientific merit and demonstrated evidence of potential benefit in ALS. Securing inclusion is itself a mark of scientific credibility.
ALS (amyotrophic lateral sclerosis), the most common form of motor neurone disease, remains an area of urgent unmet medical need with limited approved therapies. The HEALEY platform was specifically designed to accelerate the development of potential new ALS treatments, making it one of the most respected trial networks in the field.
For NUZ-001, participation in this trial network amplifies credibility. A positive topline result from a HEALEY platform regimen carries institutional weight that extends well beyond the trial itself, informing both regulatory discussions and commercial partnership negotiations.
Financially disciplined expansion — fully funded through to topline results
Cost structure remains intact
The expanded trial design has been structured to have no impact on Neurizon’s expected costs through to topline results. The modest overall increase in the total cost of completing the full trial is expected to be offset through three mechanisms:
- A philanthropic contribution from the Sean M. Healey & AMG Center for ALS at Mass General Brigham
- Eligibility under the Australian Federal Government’s R&D Tax Incentive Program
- Diligent cost management and rapid recruitment efficiencies
The Company has confirmed it remains fully funded through to trial completion.
Trial milestones at a glance
| Metric | Previous | Updated | Status | Notes |
|---|---|---|---|---|
| Total participants | 160 | 240 | Expanded | 180 NUZ-001 / 60 placebo |
| Participants assigned | — | 113 | As of 22 May 2026 | — |
| Participants dosed | — | 74 | As of 22 May 2026 | — |
| Last participant dosing | Prior projection | Q2 CY2027 | Accelerated | — |
| Topline results | Prior projection | Early Q3 CY2027 | Accelerated | — |
Director and investigator voices
Interim Executive Chairman Sergio Duchini commented on both the strategic rationale and the path ahead for NUZ-001.
Sergio Duchini, Interim Executive Chairman
“The expansion of Regimen I to 240 participants reflects our considerable confidence in NUZ-001 and is underpinned by strong momentum being delivered across the HEALEY ALS Platform Trial study. Importantly, this decision maintains the statistical power for the analysis of the primary endpoint and the potential for topline results ahead of our previously stated schedule.”
Merit Cudkowicz, MD, MSc, Director of the Healey & AMG Center and Executive Director of the Mass General Brigham Neuroscience Institute, highlighted the collaborative foundation underpinning the expanded regimen.
Merit Cudkowicz, MD, MSc, Director, Healey & AMG Center
“This partnership with Neurizon reflects a shared commitment to advancing meaningful science while keeping people living with ALS at the center of everything we do. We thank our patient advisory committee members and the entire ALS community for active participation in this important clinical trial. By working collaboratively, we can accelerate progress, strengthen the research ecosystem, and ultimately deliver solutions that better serve the ALS community.”
The next major ASX story will hit our subscribers first
What comes next for Neurizon and NUZ-001
With topline results targeted for early Q3 CY2027 and the Company confirmed as fully funded through to that milestone, Neurizon is advancing toward what management describes as a pivotal data readout from a scientifically strengthened position.
The expanded dataset is expected to enhance future regulatory, partnering, and commercial opportunities for NUZ-001. Management has also noted the broader relevance of the biomarker and translational insights expected to emerge from the trial, given NUZ-001’s potential applications across the wider neurodegenerative disease landscape.
Investors seeking further detail on the trial expansion can register for the shareholder webinar scheduled for 28 May 2026 at 4:00pm AEST. Registration is available at https://bit.ly/NUZ-001, and participants are encouraged to submit questions in advance via the registration process or by emailing enquiries@neurizon.com.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.